Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas at all stages of development, fostering increased exchange between DTMI researchers, and Bristol-Myers Squibb scientists and project teams.

For the first project, DTMI translational researchers led by Drs. Paul Noble and John Sundy will work with Bristol-Myers Squibb scientists on the clinical development of BMS-986202, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist under investigation to treat idiopathic pulmonary fibrosis (IPF). The cross-organizational team will co-develop and co-implement the protocol for a Phase II study that is expected to begin in late 2012, and will undertake biomarker validation studies. IPF is a chronic, progressive form of lung disease characterized by fibrosis, or scarring of lung tissue, with limited treatment options.

Future projects could include working together to accelerate promising investigational drugs into proof-of-concept studies, improving enrollment in clinical trials, and developing disease educational programs.

"More and more, scientific innovation in drug development is happening at the crossroad of different disciplines; so, it is important to nurture relationships at these crossroads," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president R&D, Bristol-Myers Squibb. "Both Bristol-Myers Squibb and DTMI have talented teams of world-class scientists and with our shared commitment to innovative solutions, our hope is that this partnership will allow the organizations to collaborate on projects involving all phases of research, development and disease education."

"We plan for this to provide an excellent example of how we can fundamentally improve the effectiveness and transparency of academic and industry partnerships and relationships," said Robert M Califf, MD, Vice Chancellor for Clinical and Translational Research and Director of the Duke Translational Medicine Institute. "Our work with Bristol-Myers Squibb takes advantage of the scientific and clinical expertise within both organizations and creates opportunities by removing barriers to collaboration, employing rigorous statistical analysis, and encouraging the groups to learn from each other, while we keep our focus on patients and improving health." Bristol-Myers Squibb and DTMI have established a joint steering committee of functional leaders and scientists that will forge the partnership, identify the points of intersection, and prioritize projects.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Duke Translational Medicine Institute
Duke University is a leading university dedicated to promoting global health through advanced biomedical research, graduate-level education in the life sciences and health professions, and delivery of patient care. Duke Translational Medicine Institute employs approximately 1300 scientists, project leaders, statisticians, biomedical informaticists, and educators. DTMI is dedicated to catalyzing translation across the continuum of scientific discovery, clinical research, care delivery, and global health.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...